Format

Send to

Choose Destination
BMJ. 1995 Apr 1;310(6983):827-30.

Prophylactic aspirin and risk of peptic ulcer bleeding.

Author information

1
West Midlands Regional Health Authority, Birmingham.

Abstract

OBJECTIVE:

To determine the risks of hospitalisation for bleeding peptic ulcer with the current prophylactic aspirin regimens of 300 mg daily or less.

DESIGN:

A case-control study with hospital and community controls.

SETTING:

Hospitals in Glasgow, Newcastle, Nottingham, Oxford, and Portsmouth.

SUBJECTS:

1121 patients with gastric or duodenal ulcer bleeding matched with hospital and community controls.

RESULTS:

144 (12.8%) cases had been regular users of aspirin (taken at least five days a week for at least the previous month) compared with 101 (9.0%) hospital and 77 (7.8%) community controls. Odds ratios were raised for all doses of aspirin taken, whether compared with hospital or community controls (compared with combined controls: 75 mg, 2.3 (95% confidence interval 1.2 to 4.4); 150 mg, 3.2 (1.7 to 6.5); 300 mg, 3.9 (2.5 to 6.3)). Results were not explained by confounding influences of age, sex, prior ulcer history or dyspepsia, or concurrent non-aspirin non-steroidal anti-inflammatory drug use. Risks seemed particularly high in patients who took non-aspirin non-steroidal anti-inflammatory drugs concurrently.

CONCLUSION:

No conventionally used prophylactic aspirin regimen seems free of the risk of peptic ulcer complications.

PMID:
7711618
PMCID:
PMC2549215
DOI:
10.1136/bmj.310.6983.827
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center